{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:49:34Z","timestamp":1789865374379,"version":"4.0.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,4]]},"abstract":"<jats:p>Advancing new O-antigen-based Shigella vaccines is critically dependent on development of an international standard serum and harmonized ELISA, demonstration of field efficacy in young children in low- and middle-income countries, and early engagement with regulators and policy makers.<\/jats:p>","DOI":"10.1093\/infdis\/jiab462","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T15:10:27Z","timestamp":1632323427000},"page":"1500-1503","source":"Crossref","is-referenced-by-count":23,"title":["Critical Needs in Advancing\n                    <i>Shigella<\/i>\n                    Vaccines for Global Health"],"prefix":"10.1093","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-0846","authenticated-orcid":false,"given":"Calman A","family":"MacLennan","sequence":"first","affiliation":[{"name":"Bill & Melinda Gates Foundation, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawsar R","family":"Talaat","sequence":"additional","affiliation":[{"name":"Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Diarrheal Disease Research, Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani","family":"Cohen","sequence":"additional","affiliation":[{"name":"School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S","family":"Riddle","sequence":"additional","affiliation":[{"name":"University of Nevada, Reno School of Medicine, Reno, Nevada, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte K","family":"Giersing","sequence":"additional","affiliation":[{"name":"World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"2022050519464070500_CIT0001","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(18)31891-9","article-title":"Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD","year":"2018","journal-title":"Lancet"},{"key":"2022050519464070500_CIT0002","author":"WHO."},{"key":"2022050519464070500_CIT0003","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the global enteric multicenter study inform vaccine development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022050519464070500_CIT0004","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"key":"2022050519464070500_CIT0005","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"2022050519464070500_CIT0006","author":"World Health Organization."},{"key":"2022050519464070500_CIT0007","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0264-410X(92)90046-M","article-title":"Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide\u2013protein conjugate vaccine is decreased by admixture of high doses of free saccharide","volume":"10","author":"Peeters","year":"1992","journal-title":"Vaccine"},{"key":"2022050519464070500_CIT0008","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1073\/pnas.0900891106","article-title":"Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates","volume":"106","author":"Robbins","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022050519464070500_CIT0009","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/cimm.1994.1006","article-title":"Immune responses to bacterial polysaccharides: terminal epitopes are more immunogenic than internal structures","volume":"153","author":"Fernandez","year":"1994","journal-title":"Cell Immunol"},{"key":"2022050519464070500_CIT0010","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/0264-410X(93)90172-T","article-title":"Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide","volume":"11","author":"Alonso de Velasco","year":"1993","journal-title":"Vaccine"},{"key":"2022050519464070500_CIT0011","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1128\/IAI.69.2.787-793.2001","article-title":"Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice","volume":"69","author":"Jansen","year":"2001","journal-title":"Infect Immun"},{"key":"2022050519464070500_CIT0012","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase i study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"2022050519464070500_CIT0013","doi-asserted-by":"crossref","first-page":"103310","DOI":"10.1016\/j.ebiom.2021.103310","article-title":"Human challenge study with a Shigella bioconjugate vaccine: analyses of clinical efficacy and correlate of protection","volume":"66","author":"Talaat","year":"2021","journal-title":"EBioMedicine"},{"key":"2022050519464070500_CIT0014","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebiom.2017.07.013","article-title":"Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe","volume":"22","author":"Launay","year":"2017","journal-title":"EBioMedicine"},{"key":"2022050519464070500_CIT0015","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3389\/fimmu.2017.01884","article-title":"A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790 GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country","volume":"8","author":"Obiero","year":"2017","journal-title":"Front Immunol"},{"key":"2022050519464070500_CIT0016","doi-asserted-by":"crossref","first-page":"101076","DOI":"10.1016\/j.eclinm.2021.101076","article-title":"Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: results from a phase 2b randomized, placebo-controlled challenge study in adults","volume":"39","author":"Frenck","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2022050519464070500_CIT0017","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022050519464070500_CIT0018","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1080\/21645515.2019.1606971","article-title":"Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis","volume":"15","author":"Cohen","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2022050519464070500_CIT0019","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/cid\/ciz909","article-title":"Consensus report on Shigella controlled human infection model: immunological assays","volume":"69","author":"Kaminski","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022050519464070500_CIT0020","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1016\/j.vaccine.2019.03.036","article-title":"How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?","volume":"37","author":"Giersing","year":"2019","journal-title":"Vaccine"},{"key":"2022050519464070500_CIT0021","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022050519464070500_CIT0022","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"2022050519464070500_CIT0023","author":"World Health Organization."},{"key":"2022050519464070500_CIT0024","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab462\/40597046\/jiab462.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/9\/1500\/43546245\/jiab462.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/9\/1500\/43546245\/jiab462.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T16:29:01Z","timestamp":1651768141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/9\/1500\/6374897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,24]]},"published-print":{"date-parts":[[2022,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab462","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,9,24]]}}}